Trade group the British Association of the Pharmaceutical Industry (ABPI) says it welcomes today’s release of the Labour Party’s manifesto aspirations to improve patient access to medicines, to be at the forefront of scientific innovation, to raise R&D investment to 3% of GDP and to increase jobs in the pharmaceutical industry. 21 November 2019
UK-based breast cancer specialist Azeria Therapeutics has completed a £32 million ($42 milion) series B financing round led by Syncona. 21 November 2019
Ono Pharmaceutical has launched Coralan (ivabradine hydrochloride), for the treatment of certain people with chronic heart failure (CHF), in Japan. 19 November 2019
Japan’s largest chemical company Mitsubishi Chemical Holdings said on Monday it will pay 491.8 billion yen ($4.52 billion) to make Mitsubishi Tanabe Pharma a fully owned subsidiary 19 November 2019
Idorsia has inked a global deal with Antares Pharma to develop a novel drug-device product, combining the heart attack medicine selatogrel with the QuickShot auto-injector. 19 November 2019
After divestment requirements and multiple delays, the USA’s Federal Trade Commission (FTC) has accepted the proposed consent order in connection with the pending $74 billion acquisition by Bristol-Myers Squibb of Celgene, thereby permitting the parties to close the transaction. 16 November 2019
Dr Theodora Ross has been appointed vice president of translational medicine for the discovery, pre-clinical and early development at Merck Research Laboratories, a division of Merck & Co. 16 November 2019
The UK’s National Institute for Health and Care Excellence (NICE) has released its final appraisal document (FAD) recommending funding for the use of Elmiron (pentosan polysulfate sodium) in England. 13 November 2019
Japan’s Otsuka and its USA-based, indirect subsidiary Avanir Pharmaceuticals have decided to continue the clinical development program of AVP-786 (a combination of deudextromethorphan hydrobromide and quinidine sulfate) for the treatment of agitation in patients with Alzheimer’s dementia. 12 November 2019
Oncology specialist Agenus has received $10 million upfront from UroGen Pharma, in return for access to the anti-CTLA-4 antibody zalifrelimab. 12 November 2019
Therapix Biosciences, an Israeli specialty, clinical-stage pharma company focusing on the development of cannabinoid-based treatments, and Canada-based Destiny Biosciences Global yesterday announced their mutual decision to discontinue negotiations on the previously -announced proposed merger. 8 November 2019
UK-incorporated Mallinckrodt today announced that Uvadex (methoxsalen) has received regulatory approval in Australia by the Therapeutic Goods Administration (TGA) for extracorporeal administration with the THERAKOS CELLEX Photopheresis System. 7 November 2019
Privately-held German drugmaker Boehringer Ingelheim has presented results from a new subgroup analyses from the Phase III INBUILD trial that showed Ofev (nintedanib) reduced the rate of lung function decline in patients with autoimmune-related interstitial lung diseases. 7 November 2019
Endo International today announced that Paul Campanelli, president and chief executive has notified his intention to retire and Endo’s board of directors is implementing its CEO succession plan. 5 November 2019
Eisai has sold ex-Japan royalty rights for the investigational anti-cancer agent tazemetostat to Royalty Pharma, for $110 million upfront and up to $220 million based on marketing approvals in the USA. 5 November 2019
Neuraxpharm Group, a central nervous system (CNS) specialist with a focus on the European market, has bought STU GmbH, a Switzerland-based developer and distributor of natural cannabidiol (CBD) consumer products. 29 October 2019
Medicines360, a global non-profit organization, today announced regulatory approval of its Liletta (levonorgestrel-releasing intrauterine system) 52mg. 28 October 2019
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Novartis has discontinued an early Phase II trial of LTP001 in idiopathic pulmonary fibrosis (IPF). The company confirmed that the decision was not related to safety, with no issues emerging in the study. 15 October 2024
US pharma major Eli Lilly has announced plans to invest around 1.5 billion renminbi ($206 million) into expanding its manufacturing facility in Suzhou, China. 15 October 2024
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024
India's Central Drugs Standard Control Organization (CDSCO) has provided a favorable recommendation for its novel antibiotic Miqnaf (nafithromycin) discovered and developed for the treatment of community-acquired bacterial pneumonia (CABP) in adults. 14 October 2024
The Danish Medicines Council (Medicinrådet), responsible for evaluating and recommending new treatments for Denmark’s healthcare system, is facing a significant increase in processing times. 14 October 2024
The South African Health Products Regulatory Authority (SAHPRA) and the Australian Therapeutic Goods Administration (TGA) have signed a Memorandum of Understanding (MoU), which will strengthen collaboration between the two health product regulators. 14 October 2024
California-based AI company Suki has raised $70 million in new funding to accelerate the growth of its AI-powered voice solutions in healthcare. 11 October 2024
Pfizer is to present initial findings from its CULTIVATE study of its sphingosine-1-phosphate (S1P) receptor modulator Velsipity (etrasimod) in Crohn’s disease (CD) at United European Gastroenterology Week 2024. 11 October 2024
Switzerland-based KeyBioscience and US pharma major Eli Lilly have agreed to extend their collaboration on the development of dual amylin calcitonin receptor agonists (DACRA), a new class of potential treatments for obesity and related disorders. 11 October 2024